TransEnterix inc (NYSE:TRXC) currently has a “Hold” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Hold” signal. While 20-Day Moving Average VS Current Price shows “Buy” Signal.
TransEnterix inc (NYSE:TRXC) gained 2.78 Percent and closed its previous trading session at $4.44. The stock traded with the average Volume of 6.4 Million at the end of last session.
TransEnterix inc (NYSE:TRXC) has the Market Capitalization of 860.87 Million. The Stock has its 52-week High of $6.04 and 52-Week Low of $0.60 and it touched its 52-week high on 06/27/18 and 52-Week Low on 08/03/17
The company reported its last earnings Actual EPS of $-0.06/share. While, the analyst predicted that the company could provide an EPS of $-0.08/share. Hence the difference between Predicted EPS and Actual EPS reported is $0.02/share which shows an Earnings Surprise of 25 Percent.
Sell side analysts plays vital role in buying and selling a stock where 1 analysts rated TransEnterix inc (NYSE:TRXC) as Buy, 0 analysts given Outperform signal, 0 reported Hold, and 0 analysts rated the stock as Sell.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 4.13% where SMA50 and SMA200 are 30.76% and 88.65% respectively.
The company shows its Return on Assets (ROA) value of -60.2%. The Return on Equity (ROE) value stands at -88.2%. While it’s Return on Investment (ROI) value is -30.5%.
TransEnterix inc (NYSE:TRXC) currently has a Weekly Volatility of 7.09% percent while its Monthly Volatility is at 11.02% percent. While talking about Performance of the Stock, TransEnterix inc currently has a Weekly performance of 8.29%, monthly performance percentage is 22.31 percent, Quarterly performance is 141.3 percent, 6 months performance shows a percent value of 120.9% and Yearly Performance is 526.94 percent.
TransEnterix Inc. designs, develops and manufactures medical-devices. It offers SPIDER(R) Surgical System, a laparoscopic surgical platform that allows intra-abdominal triangulation procedures to be performed with articulating instruments through a single site. The company is primarily focused on the development and commercialization of SurgiBot, a patient-side minimally invasive surgical robotic system. TransEnterix Inc., formerly known as SafeStitch Medical, Inc., is based in United States.